Scholarlink

Introduction <p>Stereotactic body radiation therapy (SBRT) is an increasingly utilized non-invasive treatment for patients with ventricular arrhythmias refractory to conventional treatments. There are limited data on long term outcomes.</p> Methods <p>Patients with ventricular arrhythmias refractory to traditional treatments underwent SBRT after a multidisciplinary discussion. Patients were followed clinically, and ventricular arrhythmia burden and ICD therapies were quantified.</p> Results <p>There were 26 patients who underwent a total of 28 SBRT sessions. Patients were followed for a median of 221 days (IQR 67, 608). Ventricular arrhythmia burden was reduced comparing a median 20 (IQR 15, 31) episodes in the 6 months pre-SBRT compared to a median 3 episodes (0,26) in the 6 months post-SBRT (<i>p</i> &lt; 0.001), excluding a 6-week blanking period. Patient mortality was 58% over follow-up and ventricular arrhythmia recurrence was 81% in those patients who survived outside of the blanking period. There were no complications related to SBRT reported.</p> Conclusions <p>In this series of patients with severe cardiomyopathy who weren’t candidates for traditional therapies and underwent palliative SBRT for ventricular arrhythmias, arrhythmia recurrence is common; however, arrhythmia burden is reduced following SBRT. Until randomized trial evidence is available, these data support SBRT as a bailout treatment option.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Extended follow-up of stereotactic body radiation therapy for refractory ventricular arrhythmias

  • 期刊论文

  • 发表日期：

    2026年3月30日

查看全文
  • Justin Hayase,
  • Jacob S. Roberts,
  • Varun Malik,
  • Robert Chin,
  • Minsong Cao,
  • Huiming Dong,
  • Kalyanam Shivkumar,
  • Jason S. Bradfield

摘要

Introduction

Stereotactic body radiation therapy (SBRT) is an increasingly utilized non-invasive treatment for patients with ventricular arrhythmias refractory to conventional treatments. There are limited data on long term outcomes.

Methods

Patients with ventricular arrhythmias refractory to traditional treatments underwent SBRT after a multidisciplinary discussion. Patients were followed clinically, and ventricular arrhythmia burden and ICD therapies were quantified.

Results

There were 26 patients who underwent a total of 28 SBRT sessions. Patients were followed for a median of 221 days (IQR 67, 608). Ventricular arrhythmia burden was reduced comparing a median 20 (IQR 15, 31) episodes in the 6 months pre-SBRT compared to a median 3 episodes (0,26) in the 6 months post-SBRT (p < 0.001), excluding a 6-week blanking period. Patient mortality was 58% over follow-up and ventricular arrhythmia recurrence was 81% in those patients who survived outside of the blanking period. There were no complications related to SBRT reported.

Conclusions

In this series of patients with severe cardiomyopathy who weren’t candidates for traditional therapies and underwent palliative SBRT for ventricular arrhythmias, arrhythmia recurrence is common; however, arrhythmia burden is reduced following SBRT. Until randomized trial evidence is available, these data support SBRT as a bailout treatment option.